Would you consider additional chemotherapy in this patient?
The patient has gone through a combination of gemcitabine and docetaxel in the frontline and adriamycin and dacarbazine as the second-line regimen. The patient also had pazopanib as the targeted therapy in the third line. Important things to address at this time, and it should be a mutual decision between the patient family and the treating team on what the goals are, are that this patient has an incurable tumor and fourth-line and beyond therapies are going to have marginal benefit that are not likely to be durable. The choice as to whether one would offer therapy or not becomes a mutual decision.
CASE: Soft-Tissue Sarcoma (Part 1)
Rachel F is a 58-year-old school teacher from Roanoke, Virginia. Her medical history is notable for mild hypertension and total knee replacement in 2011
Follow-up CT scan in January 2014 showed progression at multiple sites; at the time of follow up, her ECOG performance status was 1, with renal and hepatic function within normal limits
In September of 2014 she returns for follow-up, unable to work with increasing fatigue and abdominal pain, and her CT scan was consistent with progressive disease
After 4 months of therapy, she presents with worsening abdominal pain and declining performance status
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More